Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sells 11,337 Shares of Stock

TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sean A. Power sold 11,337 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the transaction, the chief financial officer now directly owns 670,632 shares of the company’s stock, valued at approximately $20,313,443.28. The trade was a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

TG Therapeutics Price Performance

TGTX stock remained flat at $28.00 during midday trading on Tuesday. 2,930,795 shares of the company’s stock were exchanged, compared to its average volume of 2,870,394. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm has a 50 day simple moving average of $31.26 and a two-hundred day simple moving average of $25.16. The firm has a market capitalization of $4.36 billion, a P/E ratio of -279.97 and a beta of 2.24. TG Therapeutics, Inc. has a fifty-two week low of $12.84 and a fifty-two week high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. During the same period in the prior year, the business earned $0.73 EPS. TG Therapeutics’s quarterly revenue was down 49.4% compared to the same quarter last year. Analysts forecast that TG Therapeutics, Inc. will post 0.17 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. TD Cowen initiated coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target on the stock. JPMorgan Chase & Co. upped their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. HC Wainwright boosted their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, StockNews.com downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. NBC Securities Inc. lifted its holdings in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 485 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in shares of TG Therapeutics in the second quarter worth $35,000. Blue Trust Inc. grew its stake in shares of TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 849 shares during the last quarter. ORG Wealth Partners LLC bought a new position in shares of TG Therapeutics during the third quarter valued at approximately $53,000. Finally, Values First Advisors Inc. purchased a new stake in shares of TG Therapeutics in the 3rd quarter worth about $58,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.